(Q37831262)

24 August 2017

1 reference

title

Hepatitis C pharmacogenetics: state of the art in 2010. (English)

1 reference

24 August 2017

1 reference

3

Stefan Zeuzem

1 reference

24 August 2017

Jean-Michel Pawlotsky

5

object named as

Jean-Michel Pawlotsky

0 references

Nezam Afdhal

object named as

Nezam H Afdhal

1

0 references

David L Thomas

9

object named as

David L Thomas

1 reference

24 August 2017

2

John G McHutchison

1 reference

24 August 2017

4

Alessandra Mangia

1 reference

24 August 2017

Jeffrey S Murray

6

1 reference

24 August 2017

Kevin V Shianna

7

1 reference

24 August 2017

Yasuhito Tanaka

8

1 reference

24 August 2017

David R Booth

10

1 reference

24 August 2017

David B Goldstein

11

1 reference

24 August 2017

Pharmacogenetics and Hepatitis C Meeting Participants

12

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 January 2011

1 reference

24 August 2017

1 reference

24 August 2017

53

1 reference

24 August 2017

336-345

1 reference

24 August 2017

1

1 reference

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

24 August 2017

1 reference

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

21 January 2018

1 reference

Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo

21 January 2018

1 reference

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

21 January 2018

1 reference

IL-28, IL-29 and their class II cytokine receptor IL-28R

21 January 2018

1 reference

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

21 January 2018

1 reference

Lambda interferon inhibits hepatitis B and C virus replication

21 January 2018

1 reference

An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity

21 January 2018

1 reference

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

21 January 2018

1 reference

Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells

21 January 2018

1 reference

Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes

21 January 2018

1 reference

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

21 January 2018

1 reference

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

21 January 2018

1 reference

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

21 January 2018

1 reference

Interferon-alfa, interferon-lambda and hepatitis C.

21 January 2018

1 reference

Pharmacogenetics in medicine: barriers, critical factors and a framework for dialogue

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.24052

1 reference

24 August 2017

1 reference